NZD/USD: RBNZ poses a risk, yet ongoing pressure expected – HSBC
NZD Faces Ongoing Pressure Despite RBNZ Policy Expectations
According to HSBC Global Research, the New Zealand Dollar (NZD) is likely to remain subdued against the US Dollar (USD) in the near term. This outlook persists even as markets anticipate further tightening from the Reserve Bank of New Zealand (RBNZ) over the next year. The upcoming RBNZ meeting on April 8 is widely expected to keep interest rates steady at 2.25%. Meanwhile, elevated oil and gas prices are contributing to higher local bond yields. Unless the RBNZ adopts a more aggressive stance than anticipated, NZD/USD is expected to stay on the back foot.
Key Drivers: RBNZ Policy and Commodity Prices
The Reserve Bank of New Zealand is scheduled to convene on April 8, with consensus forecasts pointing to no change in the policy rate, which should remain at 2.25% (Bloomberg, March 25, 2026).
Nonetheless, the yield curve now signals that markets are factoring in additional RBNZ rate hikes over the coming year. This shift is largely attributed to rising oil and gas prices, a trend linked to ongoing tensions in the Middle East.
Interest rates in New Zealand have climbed relative to those in Australia, lending some support to the NZD against the AUD.
However, barring a surprisingly hawkish move from the RBNZ, the New Zealand Dollar is expected to remain under downward pressure in the weeks ahead.
(This report was produced with assistance from artificial intelligence and subsequently reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
